- Home
- EXEL
EXEL
Exelixis Inc.
as 03-25-2025 12:32pm EST
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 9.4B | IPO Year: | 2000 |
| Target Price: | $37.59 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.76 | EPS Growth: | 170.77 |
| 52 Week Low/High: | $20.14 - $40.02 | Next Earning Date: | 04-29-2025 |
| Revenue: | $2,168,701,000 | Revenue Growth: | 18.50% |
| Revenue Growth (this year): | 5.45% | Revenue Growth (next year): | 10.32% |
Stock Insider Trading Activity of Exelixis Inc. (EXEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Haley Patrick J. | EXEL | EVP, Commercial | Mar 3 '25 | Sell | $38.80 | 10,000 | $388,000.00 | 341,028 | |
| WYSZOMIERSKI JACK L | EXEL | Director | Feb 28 '25 | Sell | $37.80 | 8,768 | $331,430.40 | 356,605 | |
| Smith Julie | EXEL | Director | Feb 27 '25 | Sell | $37.88 | 73,808 | $2,804,459.10 | 10,778 | |
| Oliver Bob | EXEL | Director | Feb 25 '25 | Sell | $37.25 | 18,647 | $694,600.75 | 33,514 | |
| Aftab Dana | EXEL | CSO/EVP Disc & Trans Research | Feb 24 '25 | Sell | $36.75 | 26,987 | $991,772.25 | 511,908 | |
| Senner Christopher J. | EXEL | EVP and CFO | Feb 24 '25 | Sell | $36.14 | 29,314 | $1,059,407.96 | 779,607 | |
| Beckerle Mary C | EXEL | Director | Feb 14 '25 | Sell | $34.89 | 12,210 | $425,878.38 | 30,406 | |
| Eckhardt Sue Gail | EXEL | Director | Feb 14 '25 | Sell | $35.03 | 11,568 | $405,111.36 | 34,262 | |
| Freire Maria C | EXEL | Director | Feb 14 '25 | Sell | $34.94 | 44,114 | $1,541,343.16 | 91,007 | |
| POSTE GEORGE | EXEL | Director | Feb 14 '25 | Sell | $34.74 | 15,874 | $551,462.76 | 169,020 |
Latest Exelixis Inc. News
EXEL Breaking Stock News: Dive into EXEL Ticker-Specific Updates for Smart Investing
Investor's Business Daily
a day ago
Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally
Zacks
4 days ago
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?
Zacks
5 days ago
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
FX Empire
6 days ago
Exelixis Growth Continues with Big Money Boosts
Insider Monkey
7 days ago
Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires
Zacks
12 days ago
Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?
MT Newswires
12 days ago
RBC Raises Price Target on Exelixis to $40 From $38, Keeps Outperform Rating
Zacks
13 days ago
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
Compare EXEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXEL Exelixis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.